Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

Ann Hematol. 2012 Nov;91(11):1825-6. doi: 10.1007/s00277-012-1477-3. Epub 2012 Apr 29.

Authors

Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

PMID: 22543830
DOI: 10.1007/s00277-012-1477-3

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzamides
Consolidation Chemotherapy
Humans
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Leukemia, Myeloid, Chronic-Phase / genetics
Leukemia, Myeloid, Chronic-Phase / metabolism
Leukemia, Promyelocytic, Acute / drug therapy*
Leukemia, Promyelocytic, Acute / genetics
Leukemia, Promyelocytic, Acute / metabolism
Male
Medication Adherence
Middle Aged
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / genetics
Neoplasms, Second Primary / metabolism
Piperazines / adverse effects
Piperazines / therapeutic use
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use
Remission Induction
Translocation, Genetic*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases